Rachel V Needham

age ~48

from Seattle, WA

Get Report

Also known as:

Rachel Helena Needham
Rachel H Needham
Rachel Helena Victoria Needham
Rachel Helena Victoria

Phone and address:: 13049 6Th Ave NW, Seattle, WA 98177

Connected to:

Rachel Needham Phones & Addresses

13049 6Th Ave NW, Seattle, WA 98177
12552 Phinney Ave, Seattle, WA 98133 • 2064177683
Tacoma, WA
Hillsboro, OR

Work

Position:

Building and Grounds Cleaning and Maintenance Occupations

Education

Degree:

High school graduate or higher

Resumes

Senior Scientist

view source

Location:

Seattle, WA

Industry:

Pharmaceuticals

Work:

Silverback Therapeutics Mar 2017 - Dec 2018
Scientist
Silverback Therapeutics Mar 2017 - Dec 2018
Senior Scientist
Juno Therapeutics, Inc. Jan 2016 - Mar 2017
Associate Scientist
Rarecyte, Inc. Sep 2015 - Dec 2015
Senior Associate Scientist
Rarecyte, Inc. Nov 2014 - Sep 2015
Associate Research Scientist

Education:

University of Puget Sound
Bachelors, Bachelor of Science, Biology Lehigh University
Master of Science, Masters, Molecular Biology

Skills:

Molecular Biology
Assay Development
Drug Discovery
Biotechnology
Immunology
Cell Biology
High Throughput Screening
Molecular Genetics
Biomarkers
Qpcr
Cell
In Vitro
Elisa
Rnai
Flow Cytometry
Pcr
Oncology
Tissue Culture
Dna
Rna Isolation
Bioassay
Biomarker Discovery
Transfection
Real Time Polymerase Chain Reaction
Single Cell
Clinical Trials

Rachel Needham

view source

Rachel Needham

view source

Us Patents

Methods And Gene Expression Signature For Wnt/B-Catenin Signaling Pathway
view source
US Patent:

20100169025, Jul 1, 2010
Filed:

Dec 18, 2009
Appl. No.:

12/641486
Inventors:

William T. Arthur - Perkasie PA, US
Brian Roberts - Brookline MA, US
Rachel Needham - Seattle WA, US
Hongyue Dai - Chestnut Hill MA, US
International Classification:

G06F 19/00
C12Q 1/68
G06N 5/02
US Classification:

702 19, 435 6, 706 54
Abstract:

Methods, biomarkers, and expression signatures are disclosed for assessing the regulation status of Wnt/β-catenin signaling pathway in a cell sample or subject. More specifically, several aspects of the invention provide a set of genes which can be used as biomarkers and gene signatures for evaluating Wnt/β-catenin pathway deregulation status in a sample; classifying a cell sample as having a deregulated or regulated Wnt/β-catenin signaling pathway; determining whether an agent modulates the Wnt/β-catenin signaling pathway in sample; predicting response of a subject to an agent that modulates the Wnt/β-catenin signaling pathway; assigning treatment to a subject; and evaluating the pharmacodynamic effects of therapies designed to regulate Wnt/β-catenin pathway signaling.